secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0000950170-25-030396
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neumora modifies KOASTAL-2/-3 MDD studies, delays data to 2026; R&D head departs
--------------------------------------------------------------------------------

- KOASTAL-2/-3 paused, resume March 2025; topline data from KOASTAL-3 in Q1 2026 and -2 in Q2 2026.
- Phase 2 bipolar depression trial for navacaprant discontinued to prioritize KOASTAL program.
- Robert Lenz, M.D., Ph.D., head of R&D, leaving company; will serve in advisory role.
- Cash, cash equivalents and marketable securities $307.6M as of Dec 31, 2024, funding into mid-2026.
- Q4 2024 net loss $58.8M vs $108.7M Q4 2023; full year net loss $243.8M vs $235.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000095017025030396/0000950170-25-030396-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000095017025030396/nmra-20250303.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-030396

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer